Cargando…

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

We report the results of a Phase I dose escalation trial of the multikinase inhibitor sorafenib in relapsed/refractory acute leukemias using an intermittent dosing regimen. Fifteen patients with advanced leukemia (Acute myeloid leukemia(AML), 2=Acute lymphoblastic leukemia(ALL), 1 Biphenotypic) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pratz, Keith W., Cho, Eunpi, Levis, Mark J., Karp, Judith E., Gore, Steven D., McDevitt, Michael, Stine, Adam, Zhao, Ming, Baker, Sharyn D., Carducci, Michael A., Wright, John J., Rudek, Michelle A., Smith, B. Douglas
Formato:	Texto
Lenguaje:	English
Publicado:	2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921005/ https://www.ncbi.nlm.nih.gov/pubmed/20535150 http://dx.doi.org/10.1038/leu.2010.132

Ejemplares similares

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2020)

Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure‐FLT3 Relationship
por: Liu, Tao, et al.
Publicado: (2018)

Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases
por: Okada, Keiko, et al.
Publicado: (2016)

Pharmacodynamic study of Disulfiram in Men with Non-metastatic Recurrent Prostate Cancer
por: Schweizer, Michael T., et al.
Publicado: (2013)

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma
por: Bröske, Ann-Marie E., et al.
Publicado: (2022)

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
por: Ramos, Nestor R., et al.
Publicado: (2015)

A phase II and pharmacodynamic study of sunitinib in relapsed/refractory oesophageal and gastro-oesophageal cancers
por: Wu, C, et al.
Publicado: (2015)

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
por: Perl, Alexander E., et al.
Publicado: (2022)

Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
por: Cummins, K D, et al.
Publicado: (2014)

Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
por: Cummins, K D, et al.
Publicado: (2014)

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia
por: Pratz, Keith W., et al.
Publicado: (2022)

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL
por: Nägele, Virginie, et al.
Publicado: (2017)

Sorafenib in patients with progressed and refractory bone tumors
por: Raciborska, Anna, et al.
Publicado: (2018)

A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies
por: Benepal, T, et al.
Publicado: (2005)

Glutamate carboxypeptidase activity in human skin biopsies as a pharmacodynamic marker for clinical studies
por: Rojas, Camilo, et al.
Publicado: (2011)

Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.
por: Gore, M. E., et al.
Publicado: (1995)

Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group
por: Buckstein, Rena, et al.
Publicado: (2011)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
por: Bohler, Jeanne, et al.
Publicado: (2022)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

Treatment for Relapsed/Refractory Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2021)

Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer
por: Worden, Francis, et al.
Publicado: (2015)

Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma
por: Zhou, Yu-bo, et al.
Publicado: (2021)

GENETIC CONTROL OF THE ANTIBODY RESPONSE : I. DEMONSTRATION OF DETERMINANT-SPECIFIC DIFFERENCES IN RESPONSE TO SYNTHETIC POLYPEPTIDE ANTIGENS IN TWO STRAINS OF INBRED MICE
por: McDevitt, Hugh O., et al.
Publicado: (1965)

GENETIC CONTROL OF THE ANTIBODY RESPONSE : II. FURTHER ANALYSIS OF THE SPECIFICITY OF DETERMINANT-SPECIFIC CONTROL, AND GENETIC ANALYSIS OF THE RESPONSE TO (H,G)-A--L IN CBA AND C57 MICE
por: McDevitt, Hugh O., et al.
Publicado: (1967)

Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
por: Smith, Catherine C., et al.
Publicado: (2022)

Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease
por: Goll, Rasmus, et al.
Publicado: (2022)

Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
por: Kang, Dongwoo, et al.
Publicado: (2021)

Super-Resolution Quantification of T2DM-Induced Mitochondrial Morphology Changes and Their Implications in Pharmacodynamics of Metformin and Sorafenib
por: Du, Yang, et al.
Publicado: (2022)

Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2023)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer
por: McFarland, Daniel C, et al.
Publicado: (2014)

Radiopharmaceuticals for Relapsed or Refractory Leukemias
por: Kunos, Charles A., et al.
Publicado: (2019)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

Sorafenib Dose Escalation is Not Uniformly Associated with Blood Pressure Elevations in Normotensive Patients with Advanced Malignancies
por: Karovic, Sanja, et al.
Publicado: (2014)

No Preferred Reference Frame at the Foundation of Quantum Mechanics
por: Stuckey, William, et al.
Publicado: (2021)

A new model for rheumatoid arthritis?
por: McDevitt, Hugh
Publicado: (2000)

CNS Voltage-gated Calcium Channel Gene Variation And Prolonged Recovery Following Sport-related Concussion
por: McDevitt, Jane
Publicado: (2016)

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia
por: Tam, Constantine S., et al.
Publicado: (2023)

Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010)

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3o0bjp4gp56fk4013oif2a16c4